AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26869631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lineage-specific chimerism testing
Number of subjects: 162
Study 26869674 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 26869675 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma
Number of subjects: 245
Study 26869675 — intervention group
Group type: COMPARATOR
Intervention: No asthma
Number of subjects: 245
Study 26869676 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 0
Study 26869676 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26869690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin + Abacavir (300 mg orally every 12 h)
Number of subjects: 26
Study 26869690 — intervention group
Group type: COMPARATOR
Intervention: Ribavirin alone (weight-based dosing)
Number of subjects: 26
Study 26870152 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose of multivitamins/minerals
Number of subjects: 97
Study 26870152 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of multivitamins/minerals
Number of subjects: 97
Study 26870152 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic supplementation (8 weeks) with multivitamins/minerals
Number of subjects: 97
Study 26870152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 26870387 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IVST in patients with ATTR
Number of subjects: 425
Study 26870387 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of restrictive pattern and low voltage
Number of subjects: 425
Study 26870733 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV, and promethazine 25 mg IV
Number of subjects: 40
Study 26870733 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy of palonosetron, dexamethasone, and promethazine
Number of subjects: 40
Study 26871197 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose imatinib plus nilotinib
Number of subjects: 10
Study 26871248 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded music-listening intervention for 3 months
Number of subjects: 150
Study 26871769 — intervention group
Group type: EXPERIMENTAL
Intervention: LncPPARδ
Number of subjects: 0
Study 26871769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of LncPPARδ and risk factors
Number of subjects: 0
Study 26871769 — intervention group
Group type: EXPERIMENTAL
Intervention: LncPPARδ silencing
Number of subjects: 0
Study 26871943 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of alcohol treatment into TB treatment
Number of subjects: 196
Study 26871943 — intervention group
Group type: COMPARATOR
Intervention: Incarceration history
Number of subjects: 196
Study 26871943 — intervention group
Group type: COMPARATOR
Intervention: Age under 41
Number of subjects: 196
Study 26871943 — intervention group
Group type: COMPARATOR
Intervention: Drug addiction
Number of subjects: 196
Study 26871943 — intervention group
Group type: COMPARATOR
Intervention: History of a sexually transmitted disease (STD)
Number of subjects: 196
Study 26871943 — intervention group
Group type: COMPARATOR
Intervention: Low social capital
Number of subjects: 196
Study 26871943 — intervention group
Group type: COMPARATOR
Intervention: Heavier alcohol use
Number of subjects: 196
Study 26872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambassadorship application
Number of subjects: 221
Study 26872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing friendships
Number of subjects: 221
Study 26872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Surplus of personal resources
Number of subjects: 221
Study 26872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-friend classmates with surplus resources
Number of subjects: 221
Study 26872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing friendship with limited resources
Number of subjects: 221
Study 26872002 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-friend classmates with limited resources
Number of subjects: 221
Study 26872154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25-hydroxyvitamin D
Number of subjects: 466
Study 26872154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25-hydroxyvitamin D with TMEM 16J rs7111432-AA
Number of subjects: 466
Study 26872154 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 25-hydroxyvitamin D with PKP3 rs10902158-GG
Number of subjects: 466
Study 26872720 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 8 (total content 13.5mg, average release rate 8μg/24h over the first year)
Number of subjects: 304
Study 26872720 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS 8
Number of subjects: 304
Study 26873642 — intervention group
Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg orally BID for 7 days with 14 days rest until disease progression
Number of subjects: 22
Study 26873687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy in women
Number of subjects: 5539
Study 26873687 — intervention group
Group type: COMPARATOR
Intervention: All ICD recipients
Number of subjects: 5539
Study 26873693 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 80
Study 26874378 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing reserve
Number of subjects: 73
Study 26874378 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent predicted oxygen uptake efficiency slope (OUES)
Number of subjects: 73
Study 26874378 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2/WR slope
Number of subjects: 73
Study 26874378 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2 at the anaerobic threshold (AT)
Number of subjects: 73
Study 26874395 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely high predischarge BP group
Number of subjects: 146
Study 26874395 — intervention group
Group type: COMPARATOR
Intervention: Moderately high predischarge BP group
Number of subjects: 146
Study 26874895 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous PCO2 (PtcCO2) monitoring
Number of subjects: 67
Study 26875023 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent/caregiver-reported family dinner frequency measures
Number of subjects: 160
Study 26875023 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-reported family dinner frequency measures
Number of subjects: 160
Study 26875023 — intervention group
Group type: EXPERIMENTAL
Intervention: Family dinner frequency measures
Number of subjects: 160
Study 26876245 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox (20 mg·kg(-1)·d(-1))
Number of subjects: 64
Study 26876309 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg daily
Number of subjects: 215
Study 26876309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 26876564 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) of the dentato-rubro-thalamic tract (DRT) and subthalamic nucleus (STN)
Number of subjects: 2
Study 26877119 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure treatment guided by the therapist
Number of subjects: 493
Study 26879105 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy density (ED) meals (142%) with larger portion sizes (200%)
Number of subjects: 120
Study 26879105 — intervention group
Group type: COMPARATOR
Intervention: Lower energy density (ED) meals (100%) with smaller portion sizes (100%)
Number of subjects: 120
Study 26879105 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion size (100%, 150%, 200%)
Number of subjects: 120
Study 26879105 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy density (100% vs 142%)
Number of subjects: 120
Study 26879222 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Eating Questionnaire (MEQ)
Number of subjects: 0
Study 26879467 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) incorporating ethmoidectomy without frontal sinusotomy
Number of subjects: 226
Study 26879467 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) incorporating frontal sinusotomy
Number of subjects: 226
Study 26879849 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MiP)
Number of subjects: 832
Study 26879979 — intervention group
Group type: EXPERIMENTAL
Intervention: Presumed sarcoidosis
Number of subjects: 0
Study 26879979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26880104 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX3)
Number of subjects: 135
Study 26880104 — intervention group
Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 135
Study 26880104 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein
Number of subjects: 135
Study 26880668 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended prediction rule including age >75 years, peripheral oedema, and systolic murmur
Number of subjects: 30
Study 26880668 — intervention group
Group type: COMPARATOR
Intervention: Original prediction rule
Number of subjects: 30
Study 26880670 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 4000
Study 26880670 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 4000
Study 26880670 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 4000
Study 26880670 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year follow-up on major events
Number of subjects: 4000
Study 26880867 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation with DC injections (50 Gy of external beam radiation in 25 fractions, 4 intratumoral injections of DCs)
Number of subjects: 18
Study 26880867 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation with DC injections
Number of subjects: 18
Study 26881241 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention programme inducing substantial weight loss (>0.5 BMI standard deviation scores) in 40 children
Number of subjects: 80
Study 26881241 — intervention group
Group type: COMPARATOR
Intervention: No weight loss in another 40 children (control group)
Number of subjects: 80
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: Interstitial lung abnormalities in FHS
Number of subjects: 10691
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: Interstitial lung abnormalities in AGES-Reykjavik
Number of subjects: 10691
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: Interstitial lung abnormalities in ECLIPSE
Number of subjects: 10691
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: FHS cohort HR
Number of subjects: 10691
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: AGES-Reykjavik cohort HR
Number of subjects: 10691
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: COPDGene cohort HR
Number of subjects: 10691
Study 26881370 — intervention group
Group type: COMPARATOR
Intervention: ECLIPSE cohort HR
Number of subjects: 10691
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 14 days
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 28 days
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 56 days
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 112 days
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score ≥2
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score of 1
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden ≥0.044 hours/day
Number of subjects: 370
Study 26882334 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden <0.044 hours/day
Number of subjects: 370
Study 26882402 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COPD with positive cultures for potentially pathogenic micro-organisms
Number of subjects: 45
Study 26882402 — intervention group
Group type: COMPARATOR
Intervention: Patients with COPD without positive cultures for potentially pathogenic micro-organisms
Number of subjects: 45
Study 26882477 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumps Detection test (prechemotherapy touch sensation deficits)
Number of subjects: 0
Study 26882477 — intervention group
Group type: EXPERIMENTAL
Intervention: High CIPN subgroup (51% of patients)
Number of subjects: 0
Study 26882477 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported numbness/tingling in high CIPN subgroup
Number of subjects: 0
Study 26882534 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Number of subjects: 136480
Study 26882534 — intervention group
Group type: COMPARATOR
Intervention: Paper records
Number of subjects: 136480
Study 26882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte density
Number of subjects: 768
Study 26882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in lymphocyte density at surgery
Number of subjects: 768
Study 26882907 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in lymphocyte density after chemotherapy
Number of subjects: 768
Study 26882910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg administered orally
Number of subjects: 10
Study 26882910 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects, mean age 36.2 years)
Number of subjects: 10
Study 26883498 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243
Study 26883498 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (plus aspirin)
Number of subjects: 7243
Study 26883583 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital PCR (dPCR) assays for detection of recurrent mutations (XPO1 E571K, EZH2 Y641N, MYD88 L265P) in plasma cfDNA.
Number of subjects: 0
Study 26883583 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of somatic mutations in cfDNA using dPCR.
Number of subjects: 0
Study 26883693 — intervention group
Group type: EXPERIMENTAL
Intervention: Solithromycin
Number of subjects: 13
Study 26884591 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib (pan-Trk inhibitor)
Number of subjects: 1
Study 26885381 — intervention group
Group type: EXPERIMENTAL
Intervention: MLE Group (5 injection sites)
Number of subjects: 49
Study 26885381 — intervention group
Group type: COMPARATOR
Intervention: non-MLE Group (4 injection sites)
Number of subjects: 49
Study 26885675 — intervention group
Group type: EXPERIMENTAL
Intervention: boceprevir (BOC)-based triple therapy
Number of subjects: 10
Study 26885686 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-toxicity conditioning regimen with busulfan (100 mg/m²/d for 4 days), fludarabine (30 mg/m²/d for 5 days), and anti-thymocyte globulins (2.5 mg/kg/d for 2 days)
Number of subjects: 30
Study 26885831 — intervention group
Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging
Number of subjects: 235
Study 26885831 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography
Number of subjects: 235
Study 26885880 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (0, 400, 1000, 2000, or 4000 IU/day)
Number of subjects: 323
Study 26885880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 26886785 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 0
Study 26886785 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship programs
Number of subjects: 0
Study 26887528 — intervention group
Group type: EXPERIMENTAL
Intervention: C-Pulse System
Number of subjects: 8
Study 26888022 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib therapy (retreatment) for a median of 16.9 months
Number of subjects: 90
Study 26888022 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib withdrawal syndrome
Number of subjects: 90
Study 26888022 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of imatinib before discontinuation
Number of subjects: 90
Study 26888022 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal residual leukemia measured by digital polymerase chain reaction
Number of subjects: 90
Study 26888022 — intervention group
Group type: COMPARATOR
Intervention: Imatinib discontinuation
Number of subjects: 90
Study 26888022 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed or worsened musculoskeletal pain and pruritus
Number of subjects: 90
Study 26888382 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin based drugs
Number of subjects: 972384
Study 26888382 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 972384
Study 26888535 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-α receptor 1 (TNF-α R1)
Number of subjects: 1244
Study 26888535 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL-6)
Number of subjects: 1244
Study 26888535 — intervention group
Group type: COMPARATOR
Intervention: Tumor necrosis factor-α receptor 1 (TNF-α R1) top quartile (>3.63 ng/L) vs bottom quartile (<2.24 ng/L)
Number of subjects: 1244
Study 26888535 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum amyloid A, CD40 ligand, and monocyte chemoattractant protein 1
Number of subjects: 1244
Study 26888594 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Number of subjects: 0
Study 26888594 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-compartment model
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body water (TBW) via van Raaij equations
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-compartment model
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Body density (Db) via air displacement plethysmography (ADP)
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Skinfold thickness (SFT)
Number of subjects: 41
Study 26888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography body density
Number of subjects: 41
Study 26888800 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet inhibition (antiplatelet therapy)
Number of subjects: 201
Study 26888975 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Number of subjects: 89
Study 26888975 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea)
Number of subjects: 89
Study 26889973 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR TKI
Number of subjects: 293
Study 26890209 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 26890209 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26890209 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing 25-hydroxyvitamin D levels
Number of subjects: 0
Study 26890209 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for patients found to be deficient or initiating ART or bisphosphonate therapy
Number of subjects: 0
Study 26890637 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FSPG
Number of subjects: 5
Study 26890637 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG
Number of subjects: 5
Study 26890637 — intervention group
Group type: COMPARATOR
Intervention: 18F-FET
Number of subjects: 5
Study 26891037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 10 μg/m
Number of subjects: 12
Study 26891037 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 20 μg/m
Number of subjects: 12
Study 26891037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 26891040 — intervention group
Group type: EXPERIMENTAL
Intervention: Late life depression patients
Number of subjects: 18
Study 26891040 — intervention group
Group type: COMPARATOR
Intervention: Normal elderly controls
Number of subjects: 18
Study 26891080 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample Confirmation Testing (SCT)
Number of subjects: 2820
Study 26892084 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus Valve implantation
Number of subjects: 120
Study 26892449 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-MLA ≤2.83 mm²
Number of subjects: 101
Study 26892449 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-MLA ≤2.85 mm² in lesions with Vsub >30.7 cm³
Number of subjects: 101
Study 26892449 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-MLA ≤2.67 mm² in lesions with Vsub ≤30.7 cm³
Number of subjects: 101
Study 26892510 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled cohort risk equation
Number of subjects: 74
Study 26892510 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum TBR values
Number of subjects: 74
Study 26892510 — intervention group
Group type: EXPERIMENTAL
Intervention: Agatston scores
Number of subjects: 74
Study 26892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 30
Study 26892585 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of calcifications and/or inflammation
Number of subjects: 30
Study 26892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Local thoracic aortic inflammation
Number of subjects: 30
Study 26892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifications of the thoracic descending aorta
Number of subjects: 30
Study 26892585 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation of the ascending aorta
Number of subjects: 30